CTOs on the Move

Kiniciti

www.kiniciti.com

 
Empowering the industry with the resources, expertise, and capital to help accelerate the advancement and adoption of cell and gene therapies.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Myriad RBM

Myriad RBM is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nile Therapeutics

Nile Therapeutics is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verastem

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay but improve the lives of patients diagnosed with cancer. Because for us, it`s personal. Our team is anchored by core values of character, urgency, respect and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence. We believe that empowering employees is what makes them truly care about the important work they do.

Tolerx

Tolerx is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tune Therapeutics

The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Tune Therapeutics is pioneering the creation of epi-therapeutic medicines with its powerful and precise epigenomic control platform, TEMPO. Unlike genome editing, TEMPO dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once. This genetic tuning approach allows us to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging. Our approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.